Gempharmatech Co. Ltd. A (SHG:688046) — Market Cap & Net Worth
Market Cap & Net Worth: Gempharmatech Co. Ltd. A (688046)
Gempharmatech Co. Ltd. A (SHG:688046) has a market capitalization of $1.22 Billion (CN¥8.35 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #8310 globally and #2137 in its home market, demonstrating a 4.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gempharmatech Co. Ltd. A's stock price CN¥20.36 by its total outstanding shares 410000000 (410.00 Million). Analyse Gempharmatech Co. Ltd. A operating cash flow efficiency to see how efficiently the company converts income to cash.
Gempharmatech Co. Ltd. A Market Cap History: 2022 to 2026
Gempharmatech Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $1.42 Billion to $1.22 Billion (2.87% CAGR).
Gempharmatech Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gempharmatech Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.12x
Gempharmatech Co. Ltd. A's market cap is 1.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.02x
Gempharmatech Co. Ltd. A's market cap is 7.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.42 Billion | $516.55 Million | $164.67 Million | 2.74x | 8.60x |
| 2023 | $1.19 Billion | $622.19 Million | $158.91 Million | 1.91x | 7.49x |
| 2024 | $770.95 Million | $686.84 Million | $109.82 Million | 1.12x | 7.02x |
Competitor Companies of 688046 by Market Capitalization
Companies near Gempharmatech Co. Ltd. A in the global market cap rankings as of May 7, 2026.
Key companies related to Gempharmatech Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Gempharmatech Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Gempharmatech Co. Ltd. A's market cap moved from $1.42 Billion to $ 1.22 Billion, with a yearly change of 2.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.22 Billion | +32.55% |
| 2025 | CN¥921.54 Million | +19.53% |
| 2024 | CN¥770.95 Million | -35.20% |
| 2023 | CN¥1.19 Billion | -16.04% |
| 2022 | CN¥1.42 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Gempharmatech Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.22 Billion USD |
| MoneyControl | $1.22 Billion USD |
| MarketWatch | $1.22 Billion USD |
| marketcap.company | $1.22 Billion USD |
| Reuters | $1.22 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more